Pinpoint Asset Management’s LakeShore Biopharma LSB Stock Holding History

Pinpoint Asset Management’s Portfolio LSB Stock Details LSB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-5,000	Closed	-$3.58K	–	134
2024 Q1	$3.58K	Hold	5,000	–	–	﹤0.01%	101
2023 Q4	$1.9K	Hold	5,000	–	–	﹤0.01%	72
2023 Q3	$2.06K	Hold	5,000	–	–	﹤0.01%	58
2023 Q2	$2	Hold	5,000	–	–	﹤0.01%	50
2023 Q1	$7.79K	Buy	+5,000	New	+$253K	﹤0.01%	70

Other funds holding LSB

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

SCM

Superstring Capital Management New York $140M AUM 323.19% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

OCM

Ovata Capital Management Hong Kong $1.33B AUM 5.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pinpoint Asset Management's LSB Position: Q2 2024 in Review

Pinpoint Asset Management sold out of LakeShore Biopharma (LSB) in Q2 2024, closing a stake of 5,000 shares — an estimated $3.58K sold.

Pinpoint Asset Management first reported a position in LSB in Q1 2023 and held it in 5 quarters. The position peaked at $7.79K in Q1 2023. 11 funds tracked by Wall St. Rank hold LSB as of Q2 2024.

Pinpoint Asset Management reported no remaining LakeShore Biopharma position as of Q2 2024 after selling out during the quarter.
Pinpoint Asset Management sold 5,000 LakeShore Biopharma shares in Q2 2024, an estimated $3.58K.
Pinpoint Asset Management first reported a position in LakeShore Biopharma in Q1 2023 and held it in 5 quarters.
Pinpoint Asset Management's LakeShore Biopharma position peaked at $7.79K in Q1 2023.
11 funds tracked by Wall St. Rank held LakeShore Biopharma as of Q2 2024.

Based on Pinpoint Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.